Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05142696
Title A Safety Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients in Combination With Carboplatin, Etoposide and Tislelizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Age Groups: senior | adult
Covered Countries USA | GBR | FRA | ESP | DEU

No variant requirements are available.